daniel drucker glp 1 You may know Ozempic or Wegovy, but did you know Drucker’s groundbreaking work on glucagon-like peptide-1 (GLP-1) is what makes them possible?, Daniel Drucker, physician, senior investigator at Daniel J. Drucker, MD |

Maximus Tribe declines to name its pharmacy partner

Expression of Matrix Metalloproteinases in Patients with Uterine Smooth Muscle Tumors: An Immunohistochemical Analysis of MMP-1 and MMP-2 Protein Expression in Leiomyoma, Uterine Smooth Muscle Tumor of Uncertain Malignant Potential, and Leiomyosarcoma

More recently GSTF2, GSTF8, GSTF10 and GSTF11 were identified as SA-binding receptor proteins in A

June 29, 2026 Over the past decade, dermatological science has u

Check If You Qualify for a Patient Assistance Program Pharmaceutical manufacturers run income-based assistance programs that can significantly reduce the cost of brand-name GLP-1 medications for qualifying patients

Your thoughtful communication can go a long way in forging a connection and helping them lose weight. Obesity is a chronic, relapsing, remitting, multifactorial disease, for which different therapies may be effective for other patients